Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.49

+1.0%

11:57 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (2834)	2/7/2001 10:52:48 AM
From: Biomaven	Read Replies (1) of 52153

Ian, This is a small (20 people) and quick (multiple doses over 2 weeks) Phase I trial. They're not looking at efficacy, so it can all be done quickly. A pre-clinical poster presentation on this drug available at: sciosinc.com Vertex and SKB seem to be the others with an oral p38 MAP kinase inhibitor in the clinic. Lots of pharmas chasing this one, with tox issues apparently a problem. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next